Anti-Bevacizumab Antibody (AY9) (recommended for ADA assay), Unconjugated, Multiple

Produktübersicht

• Artikelname: Anti-Bevacizumab Antibody (AY9) (recommended for ADA assay), Unconjugated, Multiple
• Artikelnummer: ABS-BEB-Y9-1MG
• Hersteller Artikelnummer: BEB-Y9-1mg
• Alternativnummer: ABS-BEB-Y9-1MG
• Hersteller: AcroBiosystems
• Wirt: Multiple
• Kategorie: Antikörper
• Spezies Reaktivität: Mouse
• Konjugation: Unconjugated

Produktbeschreibung

A recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab contains human framework regions and the complementaritydetermining regions of a murine antibody that binds to VEGF. Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons. - Antikörper

Produkteigenschaften

• Puffer: Tris with Glycine, Arginine and NaCl, pH7.5
• Reinheit: 0.95
• Formulierung: Powder
• Target-Kategorie: Bevacizumab

Bilder

Anti-Bevacizumab Antibodies bridging ELISA for Anti-Drug Antibody (ADA) assay development. Immobilized bevacizumab at 1 µg/mL, add increasing concentrations of Anti-Bevacizumab Antibody (AY9) (Cat. No. BEB-Y9, 10% human serum) and then add biotinylated bevacizumab at 5 µg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 9 ng/mL (QC tested).

Demonstration of the specificity of Anti-Bevacizumab Antibody (AY9) (Cat. No. BEB-Y9) to the bevacizumab.

Anti-Bevacizumab Antibody (AY9) on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 0.95.

BEB-Y9-1mg